Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy

Affiliations

• ¹ Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
• ² Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ³ Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁴ Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center at Houston, Houston, TX, USA.
• ⁵ Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁶ Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁷ Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁸ Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. moulder_stacy@lilly.com.
• ⁹ Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. cyam@mdanderson.org.